SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist
AbstractPurpose of ReviewThe overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.Recent FindingsCutaneous eruptions associated with COVID-19 infection have a reported frequency of 1 –20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequen...
Source: Current Dermatology Reports - October 19, 2022 Category: Dermatology Source Type: research
Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin
AbstractPurpose of ReviewThis review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic.Recent FindingsThe most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vacc...
Source: Current Dermatology Reports - October 17, 2022 Category: Dermatology Source Type: research
Epidemiology of Hidradenitis Suppurativa: Current Status
AbstractPurpose of ReviewThis review aimed to provide a comprehensive and current state of art about epidemiology and clinical aspects of the HS.Recent FindingsOur search yielded 17 articles that included studies that showed a prevalence range from 0.00033 to 1.4%. Incidence data is limited. HS is more prevalent in women than in men. The highest prevalence is found in the third and fourth decade of life. The most frequent localizations are the inguinal, axillary, and perianal regions. There are associations between HS and obesity (OR 2.09), hypertension (OR 1.84), and dyslipidemia (OR 4.06), among others.SummaryHidradeniti...
Source: Current Dermatology Reports - October 11, 2022 Category: Dermatology Source Type: research
Off-Label Uses of Rituximab in Dermatology
AbstractPurpose of ReviewRituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions.Recent FindingsKey recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus.SummaryData from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculit...
Source: Current Dermatology Reports - October 6, 2022 Category: Dermatology Source Type: research
Tattoo-Related Allergic Contact Dermatitis
AbstractPurpose of ReviewThe purpose of this article is to review the tattooing process and relevant sources of contact allergens to help clinicians manage tattoo-related allergic contact dermatitis (ACD).Recent FindingsThough tattoo-related ACD has been largely attributed to heavy metal pigments, organic pigments are more commonly used today. Sources of contact allergens may include tattoo pigments, inks, needles, and aftercare products. Allergens in inks may not be present in free form but rather formed from a process of haptenization in the dermis or from breakdown products. Because of this, tattoo inks may not elicit p...
Source: Current Dermatology Reports - October 6, 2022 Category: Dermatology Source Type: research
Off-Label Uses of Rituximab in Dermatology
AbstractPurpose of ReviewRituximab has transformed the treatment of B-cell malignancies and rheumatoid arthritis in the past 2 decades. More recently, this anti-CD20 monoclonal antibody has seen increasing usage in the field of dermatology. This review highlights the evidence supporting its use in several important dermatologic conditions.Recent FindingsKey recent findings include the 2018 FDA approval of rituximab for the treatment of moderate-to-severe pemphigus.SummaryData from randomized controlled trials have demonstrated the efficacy of rituximab in pemphigus, ANCA-associated vasculitis, and cryoglobulinemic vasculit...
Source: Current Dermatology Reports - October 6, 2022 Category: Dermatology Source Type: research
Strategies for Effective Management of Hidradenitis Suppurativa in the Hospital Setting
AbstractPurpose of ReviewHidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by acute disease flares which result in high utilization of hospital and emergency department services. This manuscript reviews evaluation and management strategies for HS in the inpatient setting.Recent FindingsRecent research highlights HS diagnosis and treatment gaps, resulting morbidity and pain, and numerous associated medical comorbidities. Evidence-based guidelines for medical and surgical therapies and comorbidity screening help inform the approach to HS management.SummaryThis systematic and evidence-based appro...
Source: Current Dermatology Reports - October 3, 2022 Category: Dermatology Source Type: research
Pemphigus for the Inpatient Dermatologist
AbstractPurpose of ReviewAlthough detailed guidelines exist for the general treatment of pemphigus, reviews specific to inpatient management are sparse. This paper will seek to provide a comprehensive and centralized guide for the treatment of this disease by the inpatient dermatologist.Recent FindingsImportant recent findings include the demonstrated efficacy of rituximab as a first-line agent in pemphigus and its approval by the FDA for the treatment of moderate-to-severe pemphigus in adults in 2018.SummaryOptimal care for pemphigus in the hospital requires a multi-disciplinary approach, which factors in specific qualiti...
Source: Current Dermatology Reports - September 2, 2022 Category: Dermatology Source Type: research
Outpatient Management of COVID-19: A Primer for the Dermatologist
AbstractPurpose of ReviewTo summarize diagnostic and therapeutic management of COVID-19 in the outpatient setting for dermatologists.Recent FindingsPaxlovid (nirmatrelvir-ritonavir) is the preferred treatment in patients with mild symptoms at high risk of progression to severe SARS-CoV2 infection. Additional options include monoclonal antibodies (bebtelovimab), remdesivir, and molnupiravir.SummaryDermatologists need to be aware of recent developments in diagnostic and therapeutic management of COVID-19 in the outpatient setting, as their patients may rely on dermatologists to provide advice, particularly in cases where tre...
Source: Current Dermatology Reports - August 20, 2022 Category: Dermatology Source Type: research
